04.15.21 GenEdge: GreenLight Strives for Global RNA Equity Share: Share on Linkedin Share on Twitter Share on Facebook Martha Ortega-Valle, co-founder of GreenLight Biosciences, is interviewed by GenEdge to discuss how RNA equity can help solve the problems of today and the future. Martha Ortega-Valle, co-founder of GreenLight Biosciences, is interviewed by GenEdge to discuss how RNA equity can help solve the problems of today and the future. Extracts from the interview are below: We were coming from a solution that could manufacture in a very integrated way mRNA for agriculture. We thought those learnings were going to play an important role to accelerate the RNA space. We decided to do it, not only the manufacturing challenge but the pipeline development….We are seeing that manufacturing and having enough vaccine doses for everyone not only in the developed world—it’s becoming an issue. Even today in Europe, countries are struggling for vaccines and doses…We have a unified way in the sense that we think RNA can solve very important problems in the agricultural space, the human health space, and even animal health…The beauty of that is that you’ll always have one single way of producing that molecule — one platform, a million products. That’s giving you R&D acceleration and then moving them through regulatory and commercial scale…In ten years, I’d like to have advanced therapies using the RNA platform that can cure or alleviate diseases that don’t have good solutions. We could think about sickle cell disease, HIV, and other important diseases…We need to make sure to integrate the local people not only in terms of getting their vaccines but also empowers them to have biomanufacturing as part of their industrial endeavors. There are wonderful universities doing great work in those locations that now have access to generate clinical materials in a facility that is local. So, it’s bringing top technologies to those locations. Read the full article here. Find out more about how GreenLight manufactures RNA here.